Related content

The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes: A New Zealand Evaluation

By Panattoni Laura   Brown Paul M.   >   Webster Mark   Gladding Patrick  

PharmacoEconomics, Vol. 30, Iss. 11, 2012-11 ,pp. : 1067-1084

Adis International

Access to resources Recommend Favorite

Beyond CYP2C19 – A New Chapter in Clopidogrel Pharmacogenomics

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 41, Iss. 1, 2011-03 ,pp. : 14-16

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reporting and Interpretation of the CYP2C19 Genotyping Test for Clopidogrel Dosing

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 8, Iss. 4, 2010-12 ,pp. : 268-272

Bentham Science Publishers

Access to resources Recommend Favorite

Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome

By  

Drug Metabolism Letters, Vol. 10, Iss. 1, 2016-03 ,pp. : 65-70

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity

By Dandara Collet   Lombard Zané   Du Plooy Ingrid   McLellan Tracy   Norris Shane A   Ramsay Michèle  

Pharmacogenomics, Vol. 12, Iss. 12, 2011-12 ,pp. : 1663-1670

Future Medicine

Access to resources Recommend Favorite